XM does not provide services to residents of the United States of America.
I
I

Illumina

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Tougher trustbusting will last beyond US election

RPT-BREAKINGVIEWS-Tougher trustbusting will last beyond US election The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Jonathan Guilford NEW YORK, July 3 (Reuters Breakingviews) - Many acquisition strategies hinge on the upcoming U.S. election. Aggressive efforts against corporate consolidation under President Joe Biden have stopped and deterred a lot of M&A activity.
A
A
G
I
M

Tougher trustbusting will last beyond US election

BREAKINGVIEWS-Tougher trustbusting will last beyond US election The author is a Reuters Breakingviews columnist. The opinions expressed are his own. Refiles to add topic codes. By Jonathan Guilford NEW YORK, July 3 (Reuters Breakingviews) - Many acquisition strategies hinge on the upcoming U.S. election. Aggressive efforts against corporate consolidation under President Joe Biden have stopped and deterred a lot of M&A activity.
A
A
G
I
M

U.S. AT&T, ATI, California Resources

U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources July 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AT&T, ATI and California Resources, on Monday. HIGHLIGHTS * AT&T Inc T.N : JP Morgan adds stock to its U.S. analyst focus list * ATI Inc ATI.N : JP Morgan removes stock from its U.S.
A
I
N
W
H
Z
T
U

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

UPDATE 2-Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2 Adds details on Grail's charge in paragraphs 4 to 6 June 27 (Reuters) - Illumina ILMN.O said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to recently spun-off cancer diagnostic test maker Grail GRAL.O . Gene-sequencing equipment maker Illumina said it will likely recognize an additional impairment charge of about $420 million for Grail's in-process researc
I

Illumina to take $1.47 billion impairment charge related to Grail in Q2

Illumina to take $1.47 billion impairment charge related to Grail in Q2 June 27 (Reuters) - Illumina ILMN.O said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc GRAL.O . Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.